107例利巴韦林不良反应分析

doi:10.19803/j.1672-8629.2022.07.16

摘要/Abstract

摘要： 目的分析利巴韦林药品不良反应(adverse drug reactions, ADR)特点,为促进临床用药安全提供参考。方法对2015年1月22日至2020年2月28日湖南长沙地区的利巴韦林ADR报告进行统计与分析。结果共有107例ADR,临床表现多样,涉及9种类型43种临床表现,在各年龄段均有分布,儿童和老年人所占比较高,男性略多于女性;静脉给药多于口服及局部给药;主要为全身性损害,胃肠系统损害;严重ADR 55例次;69例ADR发生时间在30 min内,停药或对症治疗后转归大多良好。结论儿童和老年人、静脉给药时更易发生ADR,使用利巴韦林30 min内应密切监测ADR。

关键词: 利巴韦林, 药品不良反应, 特殊人群, 安全用药

Abstract: Objective To analyze the adverse drug reactions (ADR) of ribavirin in order to provide reference for the safety of clinical medications. Methods Adverse reaction reports of ribavirin collected between January 22, 2015 and February 28, 2020 in Changsha were statistically analyzed. Results The clinical manifestations of ADR caused by ribavirin were complicated and diverse, involving 107 patients. Forty-three different clinical manifestations of nine types of ADR were observed in various age groups. The proportion of children and the elderly was higher, and males slightly outnumbered females. Intravenous administration was more common than oral or inhaled administration. The main ADR were systemic damage and damage to the gastrointestinal system. There were 55 cases of severe ADR. ADR occurred within 30 minutes of medication in 69 patients, and most of them were relieved after drug withdrawal or symptomatic treatment. Conclusion Adverse reactions of ribavirin have various clinical manifestations, to which children, the elderly and patients receiving intravenous administration are more vulnerable. Adverse reactions should be closely monitored within 30 minutes of RBV administration.

Key words: ribavirin, adverse drug reaction, special populations, safe medication

中图分类号:

李美云, 唐广良, 陈志宏, 何鑫, 陈沈珏, 李昕, 刘丽华. 107例利巴韦林不良反应分析[J]. 中国药物警戒, 2022, 19(7): 770-774.

LI Meiyun, TANG Guangliang, CHEN Zhihong, HE Xin, CHEN Shenjue, LI Xin, LIU Lihua. Analysis of 107 reports of ADR induced by ribavirin[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 770-774.

参考文献

[1] CHEN XQ, JIN YY, TANG G. New Pharmacology(新药理学)[M]. Beijing: People's Medical Publishing House, 2018.
[2] Chinese Society of Hepatology, Chinese Society of Infectious Diseases. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. Chinese Journal of Clinical Infectious Diseases(中华临床感染病杂志), 2019, 12(6): 429-450.
[3] National Administration of Traditional Chinese Medicine, National Health Commission. COVID-19 diagnosis and treatment protocol (Trial 5th Revised Version)[J].Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2020, 40(2): 136-138.
[4] GUO JR, ZHANG JW, ZHAO L.Analysis of 1071 reports of ADR/ADE induced by ribavirin[J]. Chinese Journal of Pharmacoe pidemiology(药物流行病学杂志), 2019, 28(4): 245-249.
[5] RAO YH.Ribavirin-induced adverse drug reactions(adrs): literature review of 183 cases[J]. Evaluation and Analysis of Drug-Use in Hospital of China(中国医院用药评价与分析), 2007, 7(2): 153-154.
[6] D'AVOLIO A, CUSATO J, DE NICOLO A, et al. Pharmacogenetics of ribavirin-induced anemia in HCV patients[J]. Pharmacogenomics, 2016, 17(8): 925-941.
[7] FDA. Prescribing information(ribavirin for capsules/oral solution)[EB/OL].(2020-01-28)[2020-06-17].https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020903s056,021546s012lbl.pdf.
[8] Committee OID.Recommendations for prevention and control of influenza in children, 2019-2020[J]. Pediatrics (Evanston), 2019, 144(4):e20192478.
[9] MATSUURA K, TANAKA Y, WATANABE T, et al.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type[J]. J Viral Hepat, 2014, 21(7): 466-474.
[10] MUCKE MM, HERRMANN E, MUCKE VT, et al.Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: a systematic review and meta-analysis[J]. Liver International, 2019, 39(9): 1652-1660.
[11] FDA. Prescribing information(ribavirin for inhalation solution)[EB/OL].(2016-01-06)[2020-06-17].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018859.
[12] WHO. WHO model list of essential medicines list:20th list [EB/OL].(2017-03)[2020-06-17]. https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-chi.pdf?ua=1.
[13] WU Y, WU T, ZHAN SY, et al.Analysis of the safety and benefit-risk of ribavirin[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2006, 15(4): 210-213.
[14] Expert group on standardized use of common cold in special population. Expert consensus on the standardized use of common cold in special populations[J]. International Journal of Respiration(国际呼吸杂志), 2015, 35(1): 1-5.
[15] Chinese Medical Association, Chinese Medical Association Publi-shing House , ChineseSociety of General Practice, et al. Guideline for primary care of acute upper respiratory tract infection (2018)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2019, 18(5): 422-426.
[16] National Health Commission of People's Republic of China, National Administration of Traditional Chinese Medicine. Protocol for diagnosis and treatment of influenza (2019 version)[J]. Chinese Journal of Clinical Infectious Diseases(中华临床感染病杂志), 2019, 12(6): 451-455
[17] HU JQ, WANG Y, BI HC, et al.Effects of magnesium isoglycyr-rhizinate, ribavirin and thymopentin injections on 4 major cyp isoenzymes activities by the cocktail approach[J]. Pharmacy Today(今日药学), 2016, 26(9): 616-620.
[18] CHEN ZY, LUO XD, HE ZY, et al.Drug-drug interactions during antiviral therapy for coronavirus disease 2019[J]. China Pharmaceuticals(中国药业), 2020, 29(12): 18-23.
[19] XIONG YZ, LEI ZB.Analysis of 31 cases of allergic shock induced by ribavirin[J]. China Pharmacy(中国药房), 2014, 25(32): 3017-3019.
[20] ZHANG J, HUAN ML, WANG YY.Safety analysis of potential concomitant use of antiviral therapy in patients with coronavirus disease 2019[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(10): 1397-1403.
[21] WANG H, GAO Z, LIN YJ, et al.Implications of previous studies on viral respiratory infections for anti-COVID-19 drug development[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2020, 37(5): 513-524.
[22] TAO YQ.Analysis of 37 cases of adverse reactions caused by ribavirin[J]. Journal of Mathematical Medicine(数理医药学杂志), 2014(5): 549-550.
[23] L ZP, LIU LM. Analysis on 56 cases of serious adverse drug reaction induced by Ribavirin injection[J]. Chinese Journal of Drug Abuse Prevention and Treatment(中国药物滥用防治杂志), 2012, 18(3): 179-182.
[24] HU QZ, LUO M, WANG HL, et al.Data mining and safety analysis of drugs for novel coronavirus pneumonia treatment based on FAERS: ribavirin[J]. Herald of Medicine(医药导报), 2020, 39(4): 513-518.
[25] DRUYTS E, THORLUND K, WU P, et al.Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis[J]. Clinic Infectious Diseases, 2013, 56(7): 961-967.
[26] CHANG CH, CHEN KY, LAI MY, et al.Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C[J]. Aliment Pharmacol Ther, 2002, 16(9):1623-1632.